KR20220143684A - 신종 코로나바이러스 감염에 대한 mRNA 백신의 조성물 및 방법 - Google Patents

신종 코로나바이러스 감염에 대한 mRNA 백신의 조성물 및 방법 Download PDF

Info

Publication number
KR20220143684A
KR20220143684A KR1020227030556A KR20227030556A KR20220143684A KR 20220143684 A KR20220143684 A KR 20220143684A KR 1020227030556 A KR1020227030556 A KR 1020227030556A KR 20227030556 A KR20227030556 A KR 20227030556A KR 20220143684 A KR20220143684 A KR 20220143684A
Authority
KR
South Korea
Prior art keywords
composition
mrna
orf
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227030556A
Other languages
English (en)
Korean (ko)
Inventor
셩가오 탕
동 센
춘 루
지양 헤
지아시 헤
패트릭 와이. 루
Original Assignee
알엔에이이뮨, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알엔에이이뮨, 인코포레이티드 filed Critical 알엔에이이뮨, 인코포레이티드
Publication of KR20220143684A publication Critical patent/KR20220143684A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
KR1020227030556A 2020-02-07 2021-02-08 신종 코로나바이러스 감염에 대한 mRNA 백신의 조성물 및 방법 Withdrawn KR20220143684A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062971834P 2020-02-07 2020-02-07
US62/971,834 2020-02-07
US202063058463P 2020-07-29 2020-07-29
US63/058,463 2020-07-29
US202063130581P 2020-12-24 2020-12-24
US63/130,581 2020-12-24
PCT/US2021/017149 WO2021159118A2 (en) 2020-02-07 2021-02-08 Composition and method of mrna vaccines against novel coronavirus infection

Publications (1)

Publication Number Publication Date
KR20220143684A true KR20220143684A (ko) 2022-10-25

Family

ID=77200778

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227030556A Withdrawn KR20220143684A (ko) 2020-02-07 2021-02-08 신종 코로나바이러스 감염에 대한 mRNA 백신의 조성물 및 방법

Country Status (11)

Country Link
US (2) US12029786B2 (https=)
EP (1) EP4100066A4 (https=)
JP (1) JP2023512833A (https=)
KR (1) KR20220143684A (https=)
CN (1) CN115297892A (https=)
AU (1) AU2021216443A1 (https=)
BR (1) BR112022015626A2 (https=)
CA (1) CA3167257A1 (https=)
IL (1) IL295360A (https=)
MX (1) MX2022009688A (https=)
WO (1) WO2021159118A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230116700A (ko) 2022-01-27 2023-08-04 에스케이바이오사이언스(주) 단백질 발현을 위한 mRNA와 이를 위한 주형

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12029786B2 (en) 2020-02-07 2024-07-09 RNAimmune, Inc. Composition and method of mRNA vaccines against novel coronavirus infection
WO2021160887A1 (en) * 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
JPWO2021181994A1 (https=) * 2020-03-10 2021-09-16
US20230313323A1 (en) * 2020-03-26 2023-10-05 Ionian Technologies, Llc Assays for detecting coronavirus disease 2019 (covid-19)
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
EP4334479A4 (en) * 2021-05-06 2025-02-19 Lu, Shi-Long DETECTION OF VIRAL VARIANTS
JP2024530672A (ja) 2021-08-11 2024-08-23 アールエヌエーイミューン、インコーポレイテッド 新規なコロナウイルス感染症に対するｍＲＮＡワクチンの組成物および方法
WO2023020939A1 (en) * 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
CN118475371A (zh) * 2021-09-22 2024-08-09 圣诺制药公司 基于组氨酸-赖氨酸共聚物形成的改善的纳米颗粒制剂
WO2023049814A2 (en) * 2021-09-22 2023-03-30 Sirnaomics, Inc. Nanoparticle pharmaceutical compositions with reduced nanoparticle size and improved polydispersity index
CN113881806A (zh) * 2021-09-23 2022-01-04 华南理工大学 基于CRISPR/Cas12a技术检测新冠病毒和69/70突变株的方法及试剂盒
EP4183409A1 (en) * 2021-11-17 2023-05-24 Charité - Universitätsmedizin Berlin Vaccine with improved immunogenicity against mutant coronaviruses
WO2023091766A2 (en) * 2021-11-19 2023-05-25 RNAimmune, Inc. Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
AU2022398292A1 (en) * 2021-11-29 2024-06-13 BioNTech SE Coronavirus vaccine
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US20250228929A1 (en) * 2022-04-03 2025-07-17 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
US20240207389A1 (en) * 2022-04-27 2024-06-27 Northwestern University Methods for improving covid vaccine immunogenicity
DE102023002588A1 (de) * 2022-06-26 2024-01-25 BioNTech SE Coronavirus-Impfstoff
WO2024002985A1 (en) * 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
US12280104B2 (en) 2022-11-01 2025-04-22 RNAimmune, Inc. Composition and methods for MRNA vaccines against novel omicron coronavirus infections
KR102832944B1 (ko) * 2024-12-27 2025-07-15 대한민국 제2형 중증급성호흡기증후군 코로나바이러스 변이들의 공통 서열을 포함하는 코로나바이러스감염증-19 범용 백신 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1270732A1 (en) * 2001-06-21 2003-01-02 Schuler, Gerold Improved transfection of eukaryontic cells with linear polynucleotides by electroporation
DE102005046490A1 (de) * 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
SG11201405542UA (en) * 2012-03-27 2014-10-30 Curevac Gmbh Artificial nucleic acid molecules
EP4011451A1 (en) * 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
CN110520155A (zh) * 2017-02-28 2019-11-29 广州纳泰生物医药技术有限公司 预防和治疗寨卡病毒感染的rna药物制剂
AU2019275071B2 (en) * 2018-05-24 2022-12-15 Sirnaomics, Inc. Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics
PH12022551788A1 (en) * 2020-01-28 2024-02-26 Codagenix Inc DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF
JP2023512519A (ja) 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
US12029786B2 (en) 2020-02-07 2024-07-09 RNAimmune, Inc. Composition and method of mRNA vaccines against novel coronavirus infection
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
US20210316002A1 (en) 2020-04-14 2021-10-14 Ut-Battelle, Llc Compositions and methods for drug delivery and treating viral infections
BR112022024662A2 (pt) 2020-06-03 2023-04-04 Regeneron Pharma Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2
EP4204015A4 (en) 2020-08-31 2025-01-01 The Board of Trustees of the Leland Stanford Junior University Systems and methods for producing rna constructs with increased translation and stability
US20250213679A1 (en) 2020-10-02 2025-07-03 Celsion Corporation Polynucleotide vaccines and methods of using the same
CN115160413B (zh) 2021-04-06 2023-11-14 清华大学 一种新型冠状病毒疫苗

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230116700A (ko) 2022-01-27 2023-08-04 에스케이바이오사이언스(주) 단백질 발현을 위한 mRNA와 이를 위한 주형

Also Published As

Publication number Publication date
WO2021159118A3 (en) 2021-10-28
IL295360A (en) 2022-10-01
EP4100066A4 (en) 2024-05-01
JP2023512833A (ja) 2023-03-29
CA3167257A1 (en) 2021-08-12
US12029786B2 (en) 2024-07-09
WO2021159118A2 (en) 2021-08-12
MX2022009688A (es) 2022-12-15
CN115297892A (zh) 2022-11-04
US20230108926A1 (en) 2023-04-06
US20220040292A1 (en) 2022-02-10
EP4100066A2 (en) 2022-12-14
BR112022015626A2 (pt) 2022-10-11
AU2021216443A1 (en) 2022-09-08
WO2021159118A8 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US12029786B2 (en) Composition and method of mRNA vaccines against novel coronavirus infection
JP2024503698A (ja) 変異型株ベースのコロナウイルスワクチン
US12280105B2 (en) Compositions and methods of mRNA vaccines against novel coronavirus infection
US20240294580A1 (en) Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
WO2022110099A1 (en) Coronavirus vaccines and uses thereof
US12280104B2 (en) Composition and methods for MRNA vaccines against novel omicron coronavirus infections
JP2023523423A (ja) ＳＡＲＳ－ＣｏＶ－２に対するワクチン及びその調製物
TW202417018A (zh) 編碼流感病毒抗原之自擴增rna
KR20230008707A (ko) 코로나바이러스 치료용 백신 조성물
WO2023051701A1 (zh) 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗
KR20250140103A (ko) 핵산 및 이의 용도
US20260083836A1 (en) Modified coronavirus spike antigen protein and uses thereof
US20260041759A1 (en) COVID19 mRNA Vaccine
KR102948559B1 (ko) 변형된 코로나바이러스 스파이크 항원 단백질 및 이의 용도
US20250002540A1 (en) Exosomal nucleic acid vaccine composition for protection against sars-cov-2 infection and disease
RU2852319C1 (ru) Иммуногенная композиция против гриппа
WO2025024336A1 (en) Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
CN116042656A (zh) 一种猴痘病毒mRNA疫苗及其制备方法与用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203